샘플 요청 목록

 카트 문의
시장보고서
상품코드
2143646

염증성 장질환(IBD) 치료제 시장

Inflammatory Bowel Disease (IBD) Therapeutics
발행일: | 리서치사: 구분자 Market Glass, Inc. | 페이지 정보: 영문 504 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



가격
PDF & Excel (Single User License) help
PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기는 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 5,850 금액 안내 화살표 ￦ 7,914,000
PDF & Excel (Team License: Up to 10 users) help
PDF & Excel 보고서를 동일 기업 내 최대 10명까지 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기가 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 이용자 1명당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 11,115 금액 안내 화살표 ￦ 15,037,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel 보고서를 동일 기업 및 100% 자회사의 모든 분이 이용하실 수 있는 라이선스입니다. 인쇄는 1인당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 17,550 금액 안내 화살표 ￦ 23,743,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 염증성 장질환(IBD) 치료제 시장은 2032년까지 284억 달러에 이를 전망입니다.

2025년에 215억 달러로 평가된 세계의 염증성 장질환(IBD) 치료제 시장은 2032년까지 284억 달러에 이른다고 전망되고 2025년부터 2032년 분석 기간 동안 CAGR 4.0%를 나타낼 것으로 예측됩니다. 본 보고서로 분석 대상이 되고 있는 부문 중 하나인 ' 크론병 ' 부문은 CAGR 4.8%를 나타내고, 분석 기간 종료시점까지 183억 달러에 이를 것으로 예상되고 있습니다.' 궤양성 대장염 ' 부문의 성장률은 분석 기간을 통해서 CAGR 2.7%로 추정되고 있습니다.

미국 시장은 59억 달러로 평가되는 한편, 중국은 CAGR 7.1%를 나타낼 것으로 예측됩니다.

미국의 염증성 장질환(IBD) 치료제 시장은 2025년에 59억 달러로 평가되었습니다. 세계 제 2위 경제 규모를 자랑하는 중국은 2025년부터 2032년 분석 기간 동안 CAGR 7.1%로 성장을 지속하여, 2032년까지 시장 규모가 59억 달러에 이를 것으로 예측됩니다. 기타 주목해야 할 지역 시장으로서는 일본과 캐나다를 들 수 있어 분석 기간 중에 각각 CAGR 1.8% 및 3.2%를 나타낼 것으로 예측됩니다. 유럽내에서는 독일이 CAGR 약 2.5%를 나타낼 것으로 예측됩니다.

염증성 장질환(IBD) 치료제 - 주요 동향 및 성장 촉진요인

염증성 장질환(IBD) 치료제는 주로 크론병이나 궤양성 대장염과 같은 소화관의 만성 염증성 질환의 증상을 관리 및 완화하기 위해 고안된 광범위한 치료법을 포함합니다. 이러한 질환은 심각한 염증을 유발하여 복통, 설사, 직장 출혈, 체중 감소 등의 증상을 초래합니다. 염증성 장질환(IBD) 치료제의 주요 목적은 관해를 유도 및 유지하고, 염증을 완화하며, 환자의 삶의 질(QOL)을 향상시키는 것입니다. 치료 옵션에는 아미노살리실산 제제, 코르티코스테로이드, 면역조절제, 생물학적 제제, 그리고 최근에는 저분자 약물 등이 포함됩니다. 면역계의 특정 성분을 표적으로 하는 생물학적 제제는 IBD 치료에 혁명을 일으켰으며, 기존 치료법에 반응하지 않는 환자들에게 증상 완화를 가져다주고 있습니다. 그러나 IBD는 증상의 발현 양상과 환자의 반응이 다양하기 때문에 치료에는 개별화된 접근이 필수적입니다.

기술의 발전과 지속적인 연구는 IBD 치료 환경에 큰 영향을 미치고 있습니다. 새로운 생물학적 제제 및 바이오시밀러의 개발로 인해 환자가 이용할 수 있는 치료 선택의 폭이 넓어졌습니다. TNF 억제제, 인테그린 억제제, 인터루킨 억제제 등을 포함한 이러한 치료법은 표적화된 작용기전을 통해 기존 치료법보다 부작용을 줄이면서 염증을 보다 효과적으로 조절하는 데 도움이 됩니다. 또한, 정밀 의학 및 약리유전학의 발전으로 인해 더욱 개인화된 치료 전략이 가능해졌으며, 개별 환자프로파일에 기반하여 치료 결과를 최적화할 수 있게 되었습니다. 첨단 영상 진단 기술과 바이오마커 등의 비침습적 진단 도구를 통해 질환 활동성 및 치료 반응을 모니터링하는 능력이 향상되어, 치료 계획을 보다 신속하고 정확하게 조정할 수 있게 되었습니다. 또한, 모바일 헬스 앱과 원격 의료를 포함한 디지털 헬스케어 기술은 환자와 의료 제공업체 간의 소통을 원활하게 함으로써 환자 관리와 치료 계획 준수를 향상시키고 있습니다.

염증성 장질환(IBD) 치료제 시장의 성장은 IBD 유병률 증가, 기술 혁신, 그리고 이 질환에 대한 인식 제고 및 진단 발전 등 여러 요인에 의해 주도되고 있습니다. 전 세계적으로, 특히 선진 지역에서 IBD 유병률이 증가하고 있어 효과적인 치료가 필요한 환자 수가 크게 늘어나고 있습니다. 생물학적 제제의 기술적 진보와 바이오시밀러의 개발로 인해 치료비가 절감되고, 첨단 치료법을 더 쉽게 이용할 수 있게 되었습니다. IBD 치료 프로토콜에 정밀 의학을 도입함으로써 더 효과적이고 개인 맞춤형 치료 접근 방식이 가능해졌으며, 이는 환자의 예후와 만족도 향상에 기여하고 있습니다. 또한, 디지털 헬스 기술의 도입은 질환 관리와 환자 참여를 촉진하여 치료 계획 준수를 뒷받침하고 있습니다. 새로운 치료법에 대한 규제 당국의 지원과 신약의 신속 승인 절차 역시 시장 성장에 기여하고 있습니다. 또한, 진행 중인 임상시험과 IBD의 병태생리에 대한 연구는 차세대 치료제 개발의 길을 열어주고 있으며, 향후 더욱 효과적이고 표적화된 치료 옵션이 기대되고 있습니다. 이러한 요인들이 결합되어 염증성 장질환(IBD) 치료제 시장의 역동적이고 급속히 진화하는 특성이 부각되고 있습니다.

부문 :

유형(크론병 유형, 궤양성 대장염 유형), 약제 클래스별(아미노 살리실산 계 약제, 코르티코스테로이드 계 약제, TNF 억제제, IL억제제, 항인 대구 인약, JAK 억제제, 기타 약제 분류), 투여 경로(경구투여, 주사 투여), 유통 채널(병원 약국, 소매 약국, 온라인 유통 채널)

주요 기업

  • Aclaris Therapeutics
  • Amgen, Inc.
  • Cosmo Pharmaceuticals
  • Dr. Falk Pharma GmbH
  • Evotec SE
  • F. Hoffmann-La Roche AG
  • Formycon
  • Gilead Sciences, Inc.
  • InDex Pharmaceuticals Holding AB
  • Kobiolabs

해당 분야의 전문가들의 관점을 바탕으로 합니다. 산업계, 기업, 학계에 걸친 분야 전문가들의 관점을 반영하여, 기존에 발표된 조사 결과 이상의 맥락을 더하고 있습니다.

시장의 초기 신호를 포착합니다. - 기존의 2차 조사에 완전히 반영되기 전에, 전문가 간의 대화, 기업의 동향, 시장과 관련된 논의를 통해 드러나는 변화를 추적합니다.

광범위하고 검증된 정보 기반을 활용합니다-컨퍼런스 세션, 기조 연설, 패널 토론, 블로그, 기업 공시 정보, 연차 보고서, 기관지 및 기타 검증된 정보원에서 얻은 인사이트를 통합하고 있습니다.

신호와 전략적 시장 방향성을 연결합니다. - 이러한 관점을 통합하여 시장이 어디로 향하고 있는지, 그 움직임을 주도하는 요인은 무엇인지, 그리고 전략에 있어 가장 중요할 가능성이 있는 동향은 무엇인지 파악합니다.

상세한 기업 정보를 제공합니다 - 시장 수준의 분석에 그치지 않고, 경쟁 환경에 참여하며 그 형성에 기여하고 있는 기업을 상세하게 검증합니다.

주요 지역 시장 점유율을 면밀히 검토합니다. - 단일 세계 시장 점유율 수치만으로는 전체적인 상황을 파악하기 어렵습니다. 경쟁 구도는 지역에 따라 크게 다를 수 있습니다. 분석상 관련성이 있는 경우, Market Glass의 보고서는 각 시장의 구조와 동향에 맞추어 상세도를 조정하여 주요 지역 시장 점유율 분석을 심층적으로 다룹니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향 및 성장 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KTH 26.10.14

Global Inflammatory Bowel Disease (IBD) Therapeutics Market to Reach US$28.4 Billion by 2032

The global market for Inflammatory Bowel Disease (IBD) Therapeutics estimated at US$21.5 Billion in the year 2025, is expected to reach US$28.4 Billion by 2032, growing at a CAGR of 4.0% over the analysis period 2025-2032. Crohn's Disease Type, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$18.3 Billion by the end of the analysis period. Growth in the Ulcerative Colitis Type segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.9 Billion While China is Forecast to Grow at 7.1% CAGR

The Inflammatory Bowel Disease (IBD) Therapeutics market in the U.S. is estimated at US$5.9 Billion in the year 2025. China, the world's second largest economy, is forecast to reach a projected market size of US$5.9 Billion by the year 2032 trailing a CAGR of 7.1% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 3.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Inflammatory Bowel Disease (IBD) Therapeutics - Key Trends and Drivers

Inflammatory Bowel Disease (IBD) therapeutics encompasses a range of treatments designed to manage and alleviate the symptoms of chronic inflammatory conditions of the gastrointestinal tract, primarily Crohn's disease and ulcerative colitis. These conditions cause severe inflammation, leading to symptoms such as abdominal pain, diarrhea, rectal bleeding, and weight loss. The primary goal of IBD therapeutics is to induce and maintain remission, reduce inflammation, and improve patients' quality of life. Treatment options include aminosalicylates, corticosteroids, immunomodulators, biologics, and, more recently, small molecule drugs. Biologics, which target specific components of the immune system, have revolutionized IBD treatment, providing relief for patients who do not respond to traditional therapies. However, the complexity of IBD, with its varying presentations and patient responses, necessitates a personalized approach to treatment.

Technological advancements and ongoing research are significantly impacting the IBD therapeutics landscape. The development of novel biologic therapies and biosimilars has expanded the range of treatment options available to patients. These therapies, including TNF inhibitors, integrin inhibitors, and interleukin inhibitors, offer targeted mechanisms of action that help control inflammation more effectively and with fewer side effects than conventional treatments. Additionally, advancements in precision medicine and pharmacogenomics are enabling more personalized treatment strategies, optimizing therapeutic outcomes based on individual patient profiles. Non-invasive diagnostic tools, such as advanced imaging techniques and biomarkers, are improving the ability to monitor disease activity and treatment response, allowing for more timely and accurate adjustments to therapeutic regimens. Furthermore, digital health technologies, including mobile health apps and telemedicine, are enhancing patient management and adherence to treatment plans by facilitating better communication between patients and healthcare providers.

The growth in the IBD therapeutics market is driven by several factors, including the increasing prevalence of IBD, technological innovations, and greater awareness and diagnosis of the condition. The rising incidence of IBD globally, particularly in developed regions, is significantly expanding the patient population in need of effective treatments. Technological advancements in biologic therapies and the development of biosimilars are reducing treatment costs and making advanced therapies more accessible. The integration of precision medicine into IBD treatment protocols is leading to more effective and personalized therapeutic approaches, improving patient outcomes and satisfaction. Additionally, the adoption of digital health technologies is facilitating better disease management and patient engagement, driving adherence to treatment plans. Regulatory support for novel therapies and expedited approval processes for new drugs are also contributing to market growth. Moreover, ongoing clinical trials and research into the pathophysiology of IBD are paving the way for the development of next-generation therapeutics, promising even more effective and targeted treatment options in the future. These combined factors underscore the dynamic and rapidly evolving nature of the IBD therapeutics market.

SCOPE OF STUDY:

The report analyzes the Inflammatory Bowel Disease (IBD) Therapeutics market by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Crohn's Disease Type, Ulcerative Colitis Type); Drug Class (Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class, Other Drug Classes); Administration Route (Oral Administration Route, Injectable Administration Route); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

  • Aclaris Therapeutics
  • Amgen, Inc.
  • Cosmo Pharmaceuticals
  • Dr. Falk Pharma GmbH
  • Evotec SE
  • F. Hoffmann-La Roche AG
  • Formycon
  • Gilead Sciences, Inc.
  • InDex Pharmaceuticals Holding AB
  • Kobiolabs

WHAT SETS THIS REPORT APART FROM OTHERS?

Grounded in Domain Expert Perspectives - Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.

Captures Early Market Signals - Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.

Draws From a Broad, Validated Intelligence Base - Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.

Connects Signals With Strategic Market Direction - Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.

Provides In-Depth Company Intelligence - Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.

Market Share Is Examined Where It Matters - A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, Market Glass reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • Global Economic Update
    • Inflammatory Bowel Disease (IBD) Therapeutics - Global Key Competitors Percentage Market Share in 2026 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for 69 Players Worldwide in 2026 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of IBD Throws the Spotlight on Growing Therapeutic Needs
    • Technological Innovations in Biologic Therapies Propel Growth in IBD Treatment Options
    • Increasing Adoption of Biosimilars Expands Addressable Market Opportunity
    • Advancements in Precision Medicine Strengthen Business Case for Personalized IBD Therapies
    • Integration of Digital Health Technologies Drives Adoption of Remote Patient Management Solutions
    • Enhanced Non-Invasive Diagnostic Tools Generates Demand for Advanced Monitoring Techniques
    • Growing Awareness and Early Diagnosis of IBD Improves Patient Outcomes
    • Ongoing Clinical Trials and Research into Pathophysiology to Shape Future Therapeutics
    • Patient Demand for Minimally Invasive Treatments Drives Adoption of New Drug Delivery Methods
    • Increasing Investment in Healthcare Infrastructure Expands Addressable Market Opportunity
    • Shift towards Personalized Medicine Generates Demand for Tailored IBD Therapeutic Approaches
    • Rising Incidence of IBD in Developed Regions Strengthens Business Case for Market Expansion
    • Development of Next-Generation Therapeutics Create New Market Opportunities
    • Economic and Social Impact of IBD Propels Demand for Effective Long-Term Treatments
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 2: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 3: World 13-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 4: World Inflammatory Bowel Disease (IBD) Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2020 through 2032
    • TABLE 5: World Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 6: World Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 7: World 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
    • TABLE 8: World Recent Past, Current & Future Analysis for Crohn's Disease Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 9: World Historic Review for Crohn's Disease Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 10: World 13-Year Perspective for Crohn's Disease Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 11: World Recent Past, Current & Future Analysis for Ulcerative Colitis Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 12: World Historic Review for Ulcerative Colitis Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 13: World 13-Year Perspective for Ulcerative Colitis Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 14: World Recent Past, Current & Future Analysis for Aminosalicylates Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 15: World Historic Review for Aminosalicylates Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 16: World 13-Year Perspective for Aminosalicylates Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 17: World Recent Past, Current & Future Analysis for Corticosteroids Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 18: World Historic Review for Corticosteroids Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 19: World 13-Year Perspective for Corticosteroids Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 20: World Recent Past, Current & Future Analysis for TNF Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 21: World Historic Review for TNF Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 22: World 13-Year Perspective for TNF Inhibitors Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 23: World Recent Past, Current & Future Analysis for IL Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 24: World Historic Review for IL Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 25: World 13-Year Perspective for IL Inhibitors Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 26: World Recent Past, Current & Future Analysis for Anti-Integrin Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 27: World Historic Review for Anti-Integrin Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 28: World 13-Year Perspective for Anti-Integrin Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 29: World Recent Past, Current & Future Analysis for JAK Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 30: World Historic Review for JAK Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 31: World 13-Year Perspective for JAK Inhibitors Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 32: World Recent Past, Current & Future Analysis for Oral Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 33: World Historic Review for Oral Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 34: World 13-Year Perspective for Oral Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 35: World Recent Past, Current & Future Analysis for Injectable Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 36: World Historic Review for Injectable Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 37: World 13-Year Perspective for Injectable Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 38: World Recent Past, Current & Future Analysis for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 39: World Historic Review for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 40: World 13-Year Perspective for Hospital Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 41: World Recent Past, Current & Future Analysis for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 42: World Historic Review for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 43: World 13-Year Perspective for Retail Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 44: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 45: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 46: World 13-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032

III. MARKET ANALYSIS

  • UNITED STATES
    • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
    • TABLE 47: USA Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 48: USA Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 49: USA 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 50: USA Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 51: USA Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 52: USA 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease Type and Ulcerative Colitis Type for the Years 2020, 2026 & 2032
    • TABLE 53: USA Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 54: USA Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 55: USA 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 56: USA Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 57: USA Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 58: USA 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Injectable Administration Route for the Years 2020, 2026 & 2032
  • CANADA
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 60: Canada Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 61: Canada 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 63: Canada Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 64: Canada 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease Type and Ulcerative Colitis Type for the Years 2020, 2026 & 2032
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 66: Canada Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 67: Canada 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 69: Canada Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 70: Canada 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Injectable Administration Route for the Years 2020, 2026 & 2032
  • JAPAN
    • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 72: Japan Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 73: Japan 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 75: Japan Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 76: Japan 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease Type and Ulcerative Colitis Type for the Years 2020, 2026 & 2032
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 78: Japan Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 79: Japan 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 81: Japan Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 82: Japan 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Injectable Administration Route for the Years 2020, 2026 & 2032
  • CHINA
    • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
    • TABLE 83: China Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 84: China Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 85: China 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 86: China Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 87: China Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 88: China 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease Type and Ulcerative Colitis Type for the Years 2020, 2026 & 2032
    • TABLE 89: China Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 90: China Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 91: China 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 92: China Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 93: China Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 94: China 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Injectable Administration Route for the Years 2020, 2026 & 2032
  • EUROPE
    • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 96: Europe Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 97: Europe 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 99: Europe Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 100: Europe 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease Type and Ulcerative Colitis Type for the Years 2020, 2026 & 2032
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 102: Europe Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 103: Europe 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 105: Europe Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 106: Europe 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020, 2026 & 2032
    • TABLE 107: Europe Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 108: Europe Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 109: Europe 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Injectable Administration Route for the Years 2020, 2026 & 2032
  • FRANCE
    • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
    • TABLE 110: France Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 111: France Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 112: France 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 113: France Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 114: France Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 115: France 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease Type and Ulcerative Colitis Type for the Years 2020, 2026 & 2032
    • TABLE 116: France Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 117: France Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 118: France 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 119: France Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 120: France Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 121: France 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Injectable Administration Route for the Years 2020, 2026 & 2032
  • GERMANY
    • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 123: Germany Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 124: Germany 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 125: Germany Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 126: Germany Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 127: Germany 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease Type and Ulcerative Colitis Type for the Years 2020, 2026 & 2032
    • TABLE 128: Germany Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 129: Germany Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 130: Germany 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 131: Germany Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 132: Germany Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 133: Germany 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Injectable Administration Route for the Years 2020, 2026 & 2032
  • ITALY
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 135: Italy Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 136: Italy 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 137: Italy Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 138: Italy Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 139: Italy 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease Type and Ulcerative Colitis Type for the Years 2020, 2026 & 2032
    • TABLE 140: Italy Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 141: Italy Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 142: Italy 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 143: Italy Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 144: Italy Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 145: Italy 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Injectable Administration Route for the Years 2020, 2026 & 2032
  • UNITED KINGDOM
    • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
    • TABLE 146: UK Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 147: UK Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 148: UK 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 149: UK Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 150: UK Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 151: UK 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease Type and Ulcerative Colitis Type for the Years 2020, 2026 & 2032
    • TABLE 152: UK Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 153: UK Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 154: UK 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 155: UK Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 156: UK Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 157: UK 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Injectable Administration Route for the Years 2020, 2026 & 2032
  • SPAIN
    • TABLE 158: Spain Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 159: Spain Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 160: Spain 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 161: Spain Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 162: Spain Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 163: Spain 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease Type and Ulcerative Colitis Type for the Years 2020, 2026 & 2032
    • TABLE 164: Spain Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 165: Spain Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 166: Spain 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 167: Spain Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 168: Spain Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 169: Spain 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Injectable Administration Route for the Years 2020, 2026 & 2032
  • RUSSIA
    • TABLE 170: Russia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 171: Russia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 172: Russia 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 173: Russia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 174: Russia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 175: Russia 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease Type and Ulcerative Colitis Type for the Years 2020, 2026 & 2032
    • TABLE 176: Russia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 177: Russia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 178: Russia 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 179: Russia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 180: Russia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 181: Russia 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Injectable Administration Route for the Years 2020, 2026 & 2032
  • REST OF EUROPE
    • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 183: Rest of Europe Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 184: Rest of Europe 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 186: Rest of Europe Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 187: Rest of Europe 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease Type and Ulcerative Colitis Type for the Years 2020, 2026 & 2032
    • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 189: Rest of Europe Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 190: Rest of Europe 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 192: Rest of Europe Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 193: Rest of Europe 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Injectable Administration Route for the Years 2020, 2026 & 2032
  • ASIA-PACIFIC
    • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
    • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 195: Asia-Pacific Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 196: Asia-Pacific 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2020, 2026 & 2032
    • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 198: Asia-Pacific Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 199: Asia-Pacific 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease Type and Ulcerative Colitis Type for the Years 2020, 2026 & 2032
    • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 201: Asia-Pacific Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 202: Asia-Pacific 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 204: Asia-Pacific Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 205: Asia-Pacific 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Injectable Administration Route for the Years 2020, 2026 & 2032
    • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 207: Asia-Pacific Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 208: Asia-Pacific 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
  • AUSTRALIA
    • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
    • TABLE 209: Australia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 210: Australia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 211: Australia 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease Type and Ulcerative Colitis Type for the Years 2020, 2026 & 2032
    • TABLE 212: Australia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 213: Australia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 214: Australia 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 215: Australia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 216: Australia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 217: Australia 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Injectable Administration Route for the Years 2020, 2026 & 2032
    • TABLE 218: Australia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 219: Australia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 220: Australia 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
  • INDIA
    • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
    • TABLE 221: India Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 222: India Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 223: India 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease Type and Ulcerative Colitis Type for the Years 2020, 2026 & 2032
    • TABLE 224: India Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 225: India Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 226: India 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 227: India Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 228: India Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 229: India 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Injectable Administration Route for the Years 2020, 2026 & 2032
    • TABLE 230: India Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 231: India Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 232: India 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
  • SOUTH KOREA
    • TABLE 233: South Korea Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 234: South Korea Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 235: South Korea 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease Type and Ulcerative Colitis Type for the Years 2020, 2026 & 2032
    • TABLE 236: South Korea Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 237: South Korea Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 238: South Korea 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 239: South Korea Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 240: South Korea Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 241: South Korea 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Injectable Administration Route for the Years 2020, 2026 & 2032
    • TABLE 242: South Korea Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 243: South Korea Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 244: South Korea 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
  • REST OF ASIA-PACIFIC
    • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 246: Rest of Asia-Pacific Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 247: Rest of Asia-Pacific 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease Type and Ulcerative Colitis Type for the Years 2020, 2026 & 2032
    • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 249: Rest of Asia-Pacific Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 250: Rest of Asia-Pacific 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 252: Rest of Asia-Pacific Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 253: Rest of Asia-Pacific 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Injectable Administration Route for the Years 2020, 2026 & 2032
    • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 255: Rest of Asia-Pacific Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 256: Rest of Asia-Pacific 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
  • LATIN AMERICA
    • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
    • TABLE 257: Latin America Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 258: Latin America Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 259: Latin America 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 260: Latin America Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 261: Latin America Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 262: Latin America 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease Type and Ulcerative Colitis Type for the Years 2020, 2026 & 2032
    • TABLE 263: Latin America Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 264: Latin America Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 265: Latin America 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 266: Latin America Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 267: Latin America Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 268: Latin America 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2020, 2026 & 2032
    • TABLE 269: Latin America Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 270: Latin America Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 271: Latin America 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Injectable Administration Route for the Years 2020, 2026 & 2032
  • ARGENTINA
    • TABLE 272: Argentina Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 273: Argentina Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 274: Argentina 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 275: Argentina Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 276: Argentina Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 277: Argentina 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease Type and Ulcerative Colitis Type for the Years 2020, 2026 & 2032
    • TABLE 278: Argentina Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 279: Argentina Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 280: Argentina 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 281: Argentina Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 282: Argentina Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 283: Argentina 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Injectable Administration Route for the Years 2020, 2026 & 2032
  • BRAZIL
    • TABLE 284: Brazil Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 285: Brazil Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 286: Brazil 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 287: Brazil Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 288: Brazil Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 289: Brazil 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease Type and Ulcerative Colitis Type for the Years 2020, 2026 & 2032
    • TABLE 290: Brazil Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 291: Brazil Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 292: Brazil 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 293: Brazil Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 294: Brazil Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 295: Brazil 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Injectable Administration Route for the Years 2020, 2026 & 2032
  • MEXICO
    • TABLE 296: Mexico Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 297: Mexico Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 298: Mexico 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 299: Mexico Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 300: Mexico Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 301: Mexico 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease Type and Ulcerative Colitis Type for the Years 2020, 2026 & 2032
    • TABLE 302: Mexico Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 303: Mexico Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 304: Mexico 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 305: Mexico Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 306: Mexico Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 307: Mexico 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Injectable Administration Route for the Years 2020, 2026 & 2032
  • REST OF LATIN AMERICA
    • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 309: Rest of Latin America Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 310: Rest of Latin America 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 312: Rest of Latin America Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 313: Rest of Latin America 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease Type and Ulcerative Colitis Type for the Years 2020, 2026 & 2032
    • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 315: Rest of Latin America Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 316: Rest of Latin America 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 318: Rest of Latin America Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 319: Rest of Latin America 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Injectable Administration Route for the Years 2020, 2026 & 2032
  • MIDDLE EAST
    • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
    • TABLE 320: Middle East Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 321: Middle East Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 322: Middle East 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 323: Middle East Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 324: Middle East Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 325: Middle East 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease Type and Ulcerative Colitis Type for the Years 2020, 2026 & 2032
    • TABLE 326: Middle East Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 327: Middle East Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 328: Middle East 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 329: Middle East Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 330: Middle East Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 331: Middle East 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2020, 2026 & 2032
    • TABLE 332: Middle East Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 333: Middle East Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 334: Middle East 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Injectable Administration Route for the Years 2020, 2026 & 2032
  • IRAN
    • TABLE 335: Iran Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 336: Iran Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 337: Iran 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 338: Iran Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 339: Iran Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 340: Iran 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease Type and Ulcerative Colitis Type for the Years 2020, 2026 & 2032
    • TABLE 341: Iran Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 342: Iran Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 343: Iran 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 344: Iran Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 345: Iran Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 346: Iran 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Injectable Administration Route for the Years 2020, 2026 & 2032
  • ISRAEL
    • TABLE 347: Israel Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 348: Israel Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 349: Israel 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 350: Israel Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 351: Israel Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 352: Israel 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease Type and Ulcerative Colitis Type for the Years 2020, 2026 & 2032
    • TABLE 353: Israel Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 354: Israel Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 355: Israel 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 356: Israel Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 357: Israel Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 358: Israel 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Injectable Administration Route for the Years 2020, 2026 & 2032
  • SAUDI ARABIA
    • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 360: Saudi Arabia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 361: Saudi Arabia 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 363: Saudi Arabia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 364: Saudi Arabia 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease Type and Ulcerative Colitis Type for the Years 2020, 2026 & 2032
    • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 366: Saudi Arabia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 367: Saudi Arabia 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 369: Saudi Arabia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 370: Saudi Arabia 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Injectable Administration Route for the Years 2020, 2026 & 2032
  • UNITED ARAB EMIRATES
    • TABLE 371: UAE Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 372: UAE Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 373: UAE 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 374: UAE Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 375: UAE Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 376: UAE 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease Type and Ulcerative Colitis Type for the Years 2020, 2026 & 2032
    • TABLE 377: UAE Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 378: UAE Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 379: UAE 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 380: UAE Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 381: UAE Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 382: UAE 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Injectable Administration Route for the Years 2020, 2026 & 2032
  • REST OF MIDDLE EAST
    • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 384: Rest of Middle East Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 385: Rest of Middle East 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 387: Rest of Middle East Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 388: Rest of Middle East 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease Type and Ulcerative Colitis Type for the Years 2020, 2026 & 2032
    • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 390: Rest of Middle East Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 391: Rest of Middle East 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 393: Rest of Middle East Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 394: Rest of Middle East 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Injectable Administration Route for the Years 2020, 2026 & 2032
  • AFRICA
    • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
    • TABLE 395: Africa Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 396: Africa Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 397: Africa 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Corticosteroids Drug Class, TNF Inhibitors Drug Class, IL Inhibitors Drug Class, Anti-Integrin Drug Class, JAK Inhibitors Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 398: Africa Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 399: Africa Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease Type and Ulcerative Colitis Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 400: Africa 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease Type and Ulcerative Colitis Type for the Years 2020, 2026 & 2032
    • TABLE 401: Africa Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 402: Africa Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 403: Africa 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 404: Africa Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 405: Africa Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Oral Administration Route and Injectable Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 406: Africa 13-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Injectable Administration Route for the Years 2020, 2026 & 2032

IV. COMPETITION

×

원하시는 정보를 찾아 드릴까요?

보안문자 새로고침
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기